Polyclonal antibody of ubiquitination-modified DNA-PKcs protein and preparation method thereof
By designing ubiquitinated modified DNA-PKcs polypeptide antigens and preparing polyclonal antibodies, the problem of difficulty in detecting Neddylation modification at the DNA-PKcs K4007 site in the prior art is solved, and a method to evaluate DNA-PKcs in DNA break repair is provided. Effective means of function and tumor effect.
Patent Information
- Application Number
- CN202311664592.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-06
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-12-06
AI Technical Summary
The prior art is difficult to effectively detect and study the Neddylation modification of the K4007 site of DNA-PKcs protein, and there is a lack of detection methods for evaluating the role of DNA-PKcs in DNA break repair function and tumors.
The ubiquitinated modified DNA-PKcs polypeptide antigen was designed and synthesized, and polyclonal antibodies were prepared through animal immunity to recognize and detect Neddylation modifications of the K4007 site of DNA-PKcs protein.
An effective method is provided to evaluate polyclonal antibodies of DNA-PKcs for DNA break repair function, which has important clinical significance, especially in the evaluation of roles in tumors and treatment strategies.
Smart Images

Figure BDA0004591375380000051 
Figure BDA0004591375380000061 
Figure BDA0004591375380000081
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of bioengineering, and specifically relates to a polyclonal antibody of a ubiquitinated DNA-PKcs protein modified with neddylation and a preparation method thereof. Background Art
[0002] DNA-PKcs, ATM and ATR belong to the PI3KK (phosphoinositide 3-kinase (PI3K)-related kinases) family. They are serine / threonine protein kinases. The three have similar domains and many common structural features. Their kinase domains are located at the C-terminus of the protein. The upstream and downstream of the kinase domain are the FAT (FRAP-ATM-TRRAP) domain and the FATC (FAT C-terminal) domain, respectively. Due to the similarity of the structure, the three have many common substrates, some overlap in function, and play a vital role in the DNA damage response process.
[0003] DNA-PKcs is encoded by the prkdc gene, which is evolutionarily conserved and expressed in almost all mammalian cells. The DNA-PKcs protein has 4128 amino acid residues, mainly containing a catalytic domain, a DNA binding domain, and a Ku binding domain. DNA-PKcs and ATM mainly respond to DSBs and are recruited to the ends of DNA breaks by the Ku70 / Ku80 and MRN complexes, respectively, while ATR mainly responds to DNA replication stress and is recruited to the ends of DNA breaks through interaction with ATRIP. Early biochemical studies found that DNA-PK prefers serine or threonine (S / TQ) followed by glutamine when phosphorylating its substrate proteins, and later it was found that the same is true for ATM and ATR.
[0004] DNA double-strand breaks (DSBs) are one of the most serious forms of DNA damage, with the most complex repair process and the greatest threat to genome stability. If DSBs are not repaired in time, it will affect the accurate transmission of genetic information and induce a variety of diseases including cancer. On the other hand, during the radiotherapy and chemotherapy of tumor patients, ionizing radiation or chemotherapy drugs will induce DSBs in cancer cells, leading to cancer cell death. After DNA double-strand breaks occur, a group of highly conserved PI3 (Phosphoinositide 3)-like kinases in the cell, including ATM, ATR and DNA-PKcs, are activated, and then phosphorylate hundreds of downstream substrates to regulate cell cycle checkpoints and DNA damage repair.
[0005] DNA-PKcs is a key protein in the upstream of the non-homologous end-joining (NHEJ) repair pathway. When DSBs occur, it can be quickly recruited to the DNA break ends by the cyclic heterodimer Ku70 / Ku80 to form a DNA-PK complex and activate the kinase activity of DNA-PKcs. Activated DNA-PKcs can phosphorylate a variety of proteins, such as histone H2AX, Chk2, P53, 53BP1, XRCC4, XLF, Ku70 / 80, Artemis, etc. It has many common substrates with ATM, such as H2AX and 53BP1, so ATM and DNA-PKcs have some overlapping functions in DNA repair and embryonic development.
[0006] When double-strand DNA breaks, the hallmark post-translational modification of DNA-PKcs is its phosphorylation, with more than 40 phosphorylation sites distributed in clusters. The most studied is phosphorylation of Thr2609. Thr2609 is mainly phosphorylated by ATM and ATR, and phosphorylation of the Thr2609 cluster is important for NHEJ because eliminating phosphorylation of these sites by alanine substitution leads to severe radiosensitivity and reduces the ability to connect DNA ends in vitro. In addition, phosphorylation of the Thr2609 cluster and / or conformational changes of DNA-PKcs facilitate its binding to other DNA repair molecules.
[0007] Another well-characterized DNA-PKcs phosphorylation cluster is the Serine 2056 (Ser2056) cluster. Serine 2056 is a bona fide autophosphorylation site for DSBs in vivo, and phosphorylation of the Ser2056 cluster is important for NHEJ, as loss of phosphorylation of this cluster results in increased radiosensitivity and reduced efficiency of DSB repair.
[0008] In addition to protein phosphorylation, protein ubiquitination is another important post-translational modification that occurs after DNA damage. After DNA double-strand breaks, a group of E2 ubiquitin cross-linking enzymes and E3 ubiquitin ligases including UBC13, RNF8 and RNF168 are recruited to the DNA damage site and ubiquitinate chromosomal proteins, such as histones H2A and H2B. After DNA double-strand breaks, H2A is ubiquitinated by RNF168 at the K13 and K15 lysine sites. Increased expression of RBX1 protein promotes the neddylation modification and increased activity of cullin1, which is a key component of the Skp1-Cullin1-Fbox ubiquitin E3 ligase. Therefore, it mediates the ubiquitination degradation of EXO1 in the G1 phase. Increased DNA-PKcs activity leads to increased expression of RBX1 protein, limits the formation of ssDNA at the DSB end, and inhibits HR repair in G1 cells.
[0009] The changes related to DNA-PKcs in tumors mainly include prkdc gene mutations and changes in DNA-PKcs expression and activity, and the changes in its activity in different tumor tissues are also different. Studies have found that the activity is enhanced in colorectal cancer and glioma, decreased in breast cancer and cervical cancer, and both increased and decreased activity have been reported in esophageal cancer and lymphoma. Increased DNA-PKcs activity is beneficial to tumors. First, the increased activity improves the NHEJ repair ability of precancerous cells to DNA damage, allowing cells to escape the fate of death. However, this repair is prone to errors, causing changes in DNA structure and promoting tumor formation. Secondly, the main mechanism of action of DNA-damaging chemotherapy drugs and radiotherapy commonly used in tumor treatment is to cause lethal double-strand breaks in DNA molecules, thereby inducing tumor cell death. The increase in DNA-PKcs activity can inhibit cell death to a certain extent and produce tolerance to radiotherapy and chemotherapy. In addition, the cells that survive in tumor tissues after radiotherapy and chemotherapy are often cells with high DNA-PKcs activity, which are insensitive to treatment, which is also the reason for poor efficacy and poor prognosis. Therefore, DNA-PKcs is a potential target for tumor treatment. Detection of DNA-PKcs and use of its inhibitors to enhance the effects of radiotherapy and chemotherapy is a new strategy.
[0010] Ubiquitination (neddylation) modification is a process in which the ATP-dependent ubiquitin-like small molecule protein Nedd8 (neural precursor cell expressed, developmentally downregulated 8) interacts with the lysine residue of the substrate protein to form a covalent bond after a series of catalytic actions by the activating enzyme E1, the conjugating enzyme E2 and the ligating enzyme E3. DNA-PKcs can regulate the repair pathway selection of DSBs at multiple cell cycle-related biochemical nodes, but it is not enough to detect only the phosphorylation of certain sites to reflect the activation state and biological function of DNA-PKcs. Since the detection methods and related research of other sites of DNA-PKcs are not perfect at present, there are also many gaps in the neddylation modification of DNA-PKcs K4007 site. Therefore, the preparation of a polyclonal antibody for the neddylation modification of the DNA-PKcs protein K4007 site is of great significance for evaluating the repair function of DNA-PKcs on DNA breaks and its role in tumors. Summary of the invention
[0011] The invention designs and synthesizes ubiquitination-like antigen polypeptides according to the DNA-PKcs protein sequence, and then uses them for animal immunization to prepare polyclonal antibodies.
[0012] In a first aspect, the present invention provides a polyclonal antibody against a tumor DNA-PKcs protein, wherein the antigenic amino acid sequence of the polyclonal antibody is shown in SEQ ID NO.1.
[0013] SEQ ID NO. 1: CMDVFVLRGGKEPSFDWK.
[0014] In a second aspect, the present invention provides a method for preparing a polyclonal antibody against a tumor DNA-PKcs protein, the method comprising the following steps:
[0015] S1. Antigen peptide design;
[0016] S2. Immunize the animal with the antigen designed in step S1;
[0017] S3. After the animal is immunized in step S2, the animal serum is obtained and purified to obtain the polyclonal antibody of the tumor DNA-PKcs protein of the present invention.
[0018] Furthermore, the antigen polypeptide is designed to perform ubiquitination-like modification on the DNA-PKcs protein, wherein the ubiquitination-like modification refers to connecting the C-terminal carboxyl group of the ubiquitination-like protein to the ε-amino group of the lysine residue of the DNA-PKcs protein.
[0019] Furthermore, the ubiquitination-modified protein is selected from one or more of LRGG, LALRGG, SUMO1, SUM02, SUM03, SUMO4, NEDD8, FAT10, FAT1, FUB1, UBL5, ISG15, UFM1, Urml, ATG12, ATG8, Apg12, MAP1LC3 and GABARAPL.
[0020] Furthermore, the ubiquitination-like protein is preferably NEDD8.
[0021] In a third aspect, the present invention provides a pharmaceutical composition of a polyclonal antibody against the tumor DNA-PKcs protein as described in the first aspect.
[0022] Furthermore, the pharmaceutical composition may further comprise an adjuvant and / or a pharmaceutically acceptable auxiliary material.
[0023] Furthermore, the composition can be prepared as a vaccine, a detection reagent or other biological diagnostic reagent.
[0024] In a fourth aspect, the present invention provides a use of a polyclonal antibody against a tumor DNA-PKcs protein as described in the first aspect in the preparation of a tumor suppressor drug.
[0025] Furthermore, the tumor includes but is not limited to small cell lung cancer, non-small cell lung cancer, ovarian cancer, endometrial cancer, breast cancer, head and neck cancer, thymoma, colorectal cancer, pancreatic cancer, prostate cancer, bladder cancer or melanoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of antibody development route and timeline;
[0027] Figure 2 Mass spectrometry results of Peptide 1;
[0028] Figure 3 Mass spectrometry results of Peptide 2;
[0029] Figure 4 Mass spectrometry results of Peptide 3;
[0030] Figure 5 Peptide 4 mass spectrometry test results;
[0031] Figure 6 Schematic diagram of antibody purification;
[0032] Figure 7 Dotblot test result diagram;
[0033] Figure 8 Immunofluorescence staining results (red dots are DNA-PKcs K4007 modification signals, blue dots are DAPI staining);
[0034] Fig. 9 Immunofluorescence staining results. DETAILED DESCRIPTION
[0035] The animals used in the present invention are 3 healthy New Zealand rabbits. The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.
[0036] Example 1 Antigen Design and Synthesis
[0037] Custom antibody development route and time Figure 1 shown.
[0038] 1. Antigen design
[0039] The DNA-PKcs protein is ubiquitinated by the ubiquitination protein NEDD8, that is, the C-terminal carboxyl group of the NEDD8 molecule is connected to the ε-amino group of the lysine site 4007 in the DNA-PKcs protein sequence, forming the ubiquitination sequence LRGG at the 4007 position.
[0040] According to the sequence information of the ubiquitination-modified DNA-PKcs protein, peptides with no more than 10 amino acids were selected around the 4007 site, and 2 modified peptides and 2 non-modified peptides were designed and synthesized. The peptide information is shown in Table 1 below.
[0041] Table 1 Peptide information
[0042]
[0043] 2. Mass spectrometry detection
[0044] The sequences of the four synthesized polypeptides are subjected to antigen mass spectrometry detection. The synthesized peptide mixture is ionized in a mass spectrometer to form charged ions. The electric field and magnetic field of the mass spectrometer separate the peptide ions with a specific mass to charge ratio (i.e., mass-to-charge ratio, M / Z). The separated ions are collected by the detector to determine the M / Z value of each ion. The M / Z of each peptide can be analyzed by the mass analyzer to obtain the M / Z spectrum of all peptides of the protein, i.e., the primary mass spectrum peak diagram of the protein. The ion selection device automatically selects peptide ions with greater intensity for secondary mass spectrometry analysis, outputs the secondary mass spectrum peak diagram of the selected peptide, and compares the primary mass spectrum peak diagram and the secondary mass spectrum peak diagram theoretically produced after the protein is digested with trypsin to identify the antigen required by the present invention.
[0045] The synthetic peptides were tested by mass spectrometry, and the results were qualified. The sequences of the four peptides were accurate, the difference between the measured mass and the theoretical mass of the four peptides was within 10ppm, and the amino acid sequence was correct (see Figure 2-5 As shown, the vertical axis represents the intensity of the ion peak, and the horizontal axis represents the ratio of mass to charge).
[0046] Example 2 Immunization of experimental animals
[0047] The two modified peptides were coupled to KLH and used for rabbit immunization.
[0048] The immunogen was diluted with saline and then mixed with the corresponding Freund's adjuvant in a 1:1 ratio. The antigen and adjuvant were completely mixed to form a stable emulsion. The antigen mixture was extracted with a syringe and injected into two points under the skin of the rabbit's shoulders and two points in the muscles of the two hind legs. The antigen was injected into each area with about 1 / 4 volume of the immunogen. In this way, the immunogen can persist and thus improve the immune response. Each rabbit was immunized 4 times, on the 1st day, 21st day, 28th day, and 35th day.
[0049] The first blood draw: on the 45th day, 30 mL of whole blood was collected and centrifuged. The supernatant was taken after centrifugation and sent to the laboratory for serum screening test, including ELISA; the second / third / 4th blood draw: on the 50th day, 65th day, and 70th day, whole blood was collected 3 times, 20 mL each time, and the supernatant was taken after centrifugation and sent to the laboratory for serum screening test.
[0050] Example 3 ELISA method to determine the calibration of antibodies
[0051] Two SPF experimental grade New Zealand white rabbits were immunized with antigenic peptides peptide1 and peptide2 respectively. The rabbits immunized with peptide1 were labeled R1 and the rabbits immunized with peptide2 were labeled R2. After multiple immunizations, ELISA screening was performed to preliminarily evaluate the titer and specificity of the antiserum.
[0052] 3.1 Serum screening ELISA test
[0053] In a 96-well ELISA plate coated with an antigen-modified peptide or a non-modified control peptide, antiserum is added at different dilution ratios for incubation, and then an enzyme-labeled secondary antibody and TMB colorimetric substrate are applied to detect the binding of the peptide and antiserum. When the absorbance at a wavelength of 450nm (OD450) is about 1, the corresponding antiserum dilution ratio is the titer of the antiserum. The serum titer is marked with gray shadows.
[0054] The results of ELISA test are shown in Table 2 below. The titer of R1 rabbit serum recognizing modified polypeptide 1 is about 1:54K, the titer of recognizing modified polypeptide 2 is about 1:6K, the titer of recognizing non-modified polypeptide 3 is about 1:6K, and it basically does not recognize non-modified polypeptide 4. The titer of R2 rabbit serum recognizing modified polypeptide 1 and modified polypeptide 2 is between 1:54K-1:486K, the titer of recognizing non-modified polypeptide 3 is between 1:486K, and it basically does not recognize non-modified polypeptide 4. In general, the antisera of R1 and R2 rabbits both showed good titers and were purified.
[0055] Table 2 Serum ELISA test results
[0056]
[0057] Example 4: Antibody purification by affinity chromatography
[0058] 4.1 Prepare protein A affinity column:
[0059] Usually, 5mL or 10mL of protein A filler is selected, and equal volumes of filler and PBS buffer solution are mixed and stirred, and air is pumped to remove bubbles in the filler. Slowly add protein A filler into the glass column to fill the chromatography column. Avoid column drying during this process. After filling, balance the column with 10 times the volume of pre-cooled PBS buffer solution.
[0060] 4.2 Protein A affinity chromatography:
[0061] 4.2.1 After filtering the serum, load it onto the balanced protein A chromatography column. To detect the binding efficiency of the antiserum to the filler, retain the load effluent.
[0062] 4.2.2 Wash the column with PBS buffer solution, and then elute with 150mM glycine buffer solution. Collect the eluate and add neutralization buffer solution to adjust the pH to 7.
[0063] 4.2.3 Load the crude pure IgG obtained after protein A purification onto the balanced antigen polypeptide affinity chromatography column to specifically enrich the target antibody.
[0064] 4.2.4 Removal of non-specific antibodies:
[0065] The target antibody obtained in the previous step is loaded onto the well-equilibrated picolinyl-modified and isonicotinoic acid-modified affinity chromatography columns, and the effluent is directly collected to remove non-specific antibody components.
[0066] 4.2.5 Antibody Storage:
[0067] Determine the protein content. Add 10% glycerol to preserve the antibody, and store the purified antibody at 2°C-8°C after aliquoting.
[0068] Schematic diagram of antibody purification Figure 6 As shown, the serum was filtered through a filter and then loaded onto a balanced protein A chromatography column to obtain ET1, ET1 was loaded onto an Antigen Peptides chromatography column to obtain ET2, and ET2 was loaded onto a non-modified control peptides chromatography column to obtain FT3.
[0069] Example 5: ELISA for antibody quality control testing
[0070] Sufficient amount of rabbit serum was taken for multi-step affinity purification, and the purified antibodies were tested by ELISA and Dot Blot.
[0071] 5.1ELISA test:
[0072] 5.1.1 Antigen coating: dilute the antigen with coating solution and add 50ug / well of the ELISA plate. Incubate in a refrigerator at 4℃ overnight or in a 37℃ oven for 2h.
[0073] 5.1.2 Washing: Take out the ELISA plate coated the day before and add 1×TBST to wash three times.
[0074] 5.1.3 Blocking: Add 1% BSA blocking solution to the cleaned ELISA plate, incubate at 37°C for 1 hour, and then wash 1-3 times.
[0075] 5.1.4 Primary antibody incubation: dilute the antibody in a 3-fold gradient starting from 1:1K. Adjust the dilution volume according to the actual situation. Add to the ELISA plate in sequence, incubate at 37℃ for 1.5h, and then wash 1-3 times.
[0076] 5.1.5 Secondary antibody incubation: Dilute the secondary antibody to 1:10K with 1% BSA blocking solution, incubate at room temperature or 37°C for 45 minutes, and then wash 1-3 times.
[0077] 5.1.6 Color development: Add TMB colorimetric solution and then add 1M sulfuric acid to terminate the display reaction 5-10 minutes later, and read the data using an ELISA reader.
[0078] The antibodies purified from the sera of R1 and R2 rabbits were labeled as Ab1 and Ab2 (Ab2 strongly recognized the non-modified peptide 3 and was discarded). The ELISA test results are shown in Table 3: the titer of Ab1 antibody recognizing the modified peptide 1 was about 1:1458K, and it did not recognize the non-modified peptides 3 and 4.
[0079] Table 3 Antibody ELISA test results
[0080]
[0081] Example 6: Dot Blot for Antibody Quality Control Testing
[0082] 6.2Dotblot detection:
[0083] 6.2.1 Spotting: Spot the uncross-linked antigen peptide onto the PVDF membrane in a gradient of 1ng, 4ng, 16ng, and 64ng.
[0084] 6.2.2 Blocking: After the membrane surface is dry, add blocking solution and block at room temperature for 60 minutes.
[0085] 6.2.3 Washing: Wash with 1× TBST for 10 min.
[0086] 6.2.4 Primary antibody incubation: dilute the antibody with 2.5-5% skim milk powder, incubate at room temperature for 2 hours, and then wash 3 times with 1×TBST, each time for 5-10 minutes.
[0087] 6.2.5 Secondary antibody incubation: Select the corresponding mouse or rabbit antibody according to the properties of the primary antibody; add the secondary antibody at a dilution ratio of 1:10K, incubate at room temperature for 45min-1h, and then wash 3 times with 1×TBST, each time for 5-10min.
[0088] 6.2.6 Add color developing substrate to the washed membrane and expose it to light.
[0089] The results are as follows Figure 7 As shown, as the sample amount gradually increased from 1 ng to 64 ng, the gray value of the Dot blot experimental results gradually increased, indicating that the purified antibody was successfully constructed and can be used for laboratory monitoring.
[0090] Example 7: Immunofluorescence staining for antibody quality control testing
[0091] 7.1BEAS-2B cells were digested and counted and then cultured on glass slides for 24 hours
[0092] 7.2 BEAS-2B cells were treated with 10 μM VP-16 for 4 hours. VP-16 caused damage to the intracellular DNA.
[0093] 7.3 Remove the culture medium from the cells, wash twice with PBS, and fix with 4% paraformaldehyde at room temperature for 15 minutes.
[0094] 7.4 After washing once with PBS, punch wells with 0.5% Triton-X100 for 10 minutes.
[0095] 7.510% FBS was blocked at room temperature for 1 hour.
[0096] 7.6 Dilute the DNA-PKcs K4007 site antibody at 1:500 and incubate the cells at room temperature for 1 hour.
[0097] 7.7 Wash three times with PBS to remove non-specific binding.
[0098] 7.8 Incubate with rhodamine TRITC-labeled goat anti-rabbit secondary antibody at room temperature for 30 minutes.
[0099] 7.9 Wash three times with PBS to remove non-specific binding.
[0100] 7.10 Seal the slides with ProLong Gold antifade sealing medium (containing the nuclear dye DAPI).
[0101] 7.11 Observe with confocal microscope and analyze the results statistically.
[0102] The results are as follows Figure 8As shown, after BEAS-2B cells were treated with 10 μM VP-16 for 4 hours, the antibody against DNAPKcs K4007 neddylation modification was able to recognize foci formed by DNA-PKcs neddylation modification.
[0103] Example 8: Immunoprecipitation-Western blot for antibody quality control detection
[0104] 8.1 Culture BEAS-2B cells and treat BEAS-2B cells with 10 μM VP-16.
[0105] 8.2 Collect VP-16-treated BEAS-2B cells at 0h, 1h, 4h, and 8h respectively.
[0106] 8.3BEAS-2B cells were lysed using RIPA lysis buffer.
[0107] 8.4 Lyse protein for BCA quantification.
[0108] 8.5 Incubate the proteins at different time points with DNA-PKcs antibody at 4 degrees overnight.
[0109] 8.6 Add Protein A / G column material and continue incubation for 4 hours.
[0110] 8.7 Centrifuge and discard the supernatant. Wash three times with lysis buffer.
[0111] 8.8 Add 5X loading buffer and heat at 95 degrees for 5 minutes to denature the protein.
[0112] 8.9 Separate each group of proteins by SDS-PAGE electrophoresis.
[0113] 8.10 Transfer the proteins separated by PAGE gel to PVDF membrane.
[0114] 8. Block PVDF with 115% skim milk for 1 hour.
[0115] 8.12 Incubate the PVDF membrane with DNA-PKcs K4007 modified antibody and DNA-PKcs antibody respectively.
[0116] 8.13After washing three times with TBST, incubate with HRP-labeled secondary antibody.
[0117] 8.14 Add HRP substrate and expose to light for development.
[0118] The results are as follows Fig. 9As shown, after BEAS-2B cells were treated with 10 μM VP-16, the neddylation modification of the DNA-PKcs K4007 site increased over time as the DNA damage time prolonged.
Claims
1. A polyclonal antibody against a tumor DNA-PKcs protein, wherein the polyclonal antibody against a tumor DNA-PKcs protein is prepared by the following method: S1. Antigen peptide design: DNA-PKcs protein is subjected to ubiquitination-like modification, wherein the ubiquitination-like modification refers to forming a ubiquitination-like sequence LRGG at position 4007 by connecting the C-terminal carboxyl group of the ubiquitination-like protein NEDD8 to the ε-amino group of the lysine residue at position 4007 of the DNA-PKcs protein sequence, and selecting polypeptides of no more than 10 amino acids at the position 4007 to design and synthesize antigen polypeptides, wherein the amino acid sequence of the antigen polypeptide is: CMDVFV(LRGG)KEPSFDWK; S2. Immunize the animal with the antigen designed in step S1; S3. After the animal is immunized in step S2, the animal serum is obtained and purified to obtain the polyclonal antibody of the tumor DNA-PKcs protein.
2. A detection reagent, comprising the polyclonal antibody against the tumor DNA-PKcs protein according to claim 1.
3. Use of the polyclonal antibody against the tumor DNA-PKcs protein as claimed in claim 1 in the preparation of a reagent for detecting DNA-PKcs repair of DNA breaks.
Citation Information
Patent Citations
DNA dependent protein kinase catalytic subunit single-chain antibody and its encoding gene and application
CN101362802A
Monoclonal antibody of catalytic subunit of DNA-dependent protein kinase and application of monoclonal antibody
CN105886475A
Method for determining liver and gall cell cancerization, its transfer and degree of malignancy
CN1566957A
Uses of DNA-PK
EP1832663A2
Dna dependent protein kinase catalytic subunit phosphorylation sites and antibodies thereto
US20050176935A1
